In our cohort, these patients did not differ from the rest in terms of survival, which might be explained by the difference in the inclusion criteria (in the above-mentioned report study participants were predominantly with locally advanced and metastatic disease), sample size (55 compared to 94 in our study), and KRAS CNG detection methodology (NGS compared to our ddPCR assay). Here, KRAS is linked to metastatic neoplasm.